Geneva, Switzerland
After three years of the COVID-19 pandemic, health systems in countries have started showing the first major signs of health system recovery, according to ...
NEW ORLEANS — The oral Janus kinase (JAK) inhibitor ivarmacitinib, which is characterized as being highly selective for the JAK1 enzyme, is effective for the treatment of atopic dermatitis (AD), ...